Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Exploration of Clinical Exploration Adeno-associated Virus Vector Expression of Human Coagulation Factor VIII Gene Therapy for Hemophilia A

Next Previous
Trial Profile

Clinical Exploration of Clinical Exploration Adeno-associated Virus Vector Expression of Human Coagulation Factor VIII Gene Therapy for Hemophilia A

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GS-001 (Primary) ; Prednisone; Tacrolimus
  • Indications Haemophilia A
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 16 Nov 2023 According to a Gritgen Therapeutics media release, company received clinical trial approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) in January of this year. The IND approval was granted by NMPA in January 2023.
  • 16 Nov 2023 According to a Gritgen Therapeutics media release, the first patient has been dosed in the China Phase 1 trial on Aug. 2, 2023.
  • 16 Nov 2023 Preliminary results from this study presented in a Gritgen Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top